Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $21,568.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $53.92, for a total transaction of $21,568.00. Following the transaction, the vice president now directly owns 55,588 shares of the company’s stock, valued at approximately $2,997,304.96. This represents a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $56.55 on Thursday. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.81. The stock’s fifty day moving average price is $56.44 and its 200-day moving average price is $58.88. The firm has a market cap of $1.19 billion, a P/E ratio of -102.82 and a beta of 0.73. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. During the same quarter in the previous year, the business posted $1.05 EPS. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. On average, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on ANIP. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Truist Financial boosted their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Piper Sandler initiated coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $77.71.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Pacer Advisors Inc. raised its position in shares of ANI Pharmaceuticals by 23,259.8% in the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after acquiring an additional 565,910 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after purchasing an additional 340,854 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of ANI Pharmaceuticals during the third quarter valued at about $13,043,000. Millennium Management LLC boosted its holdings in shares of ANI Pharmaceuticals by 1,005.8% in the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after buying an additional 209,272 shares in the last quarter. Finally, Mizuho Markets Americas LLC purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter worth approximately $11,670,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.